News

The proprietary synthetic molecules called Antibody Recruiting Molecules (ARMs) are developed by professor David Spiegel and his team at Yale University. The ARMs work by harnessing the power

Portage holds 54% equity interest in Biohaven, which filed an investigational drug application (IND) regarding BHV-0223 and recently secured approval from the US Food and Drug Administration (FDA)

Tarloxotinib is the company’s hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand. The company noted that elevated expression

Earlier, the FDA has approved Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin), while Synjardy is the third product containing empagliflozin that received approval from the agency. Both empagliflozin and metformin

The company paid $232 per share in cash for Receptos, which is focused on developing therapeutic candidates to treat immune and metabolic diseases. The acquisition of Receptos builds

The two-year project, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), will allow Symic to perform additional preclinical efficacy studies and advance lead

Under the deal, Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. RHB-105 is a new fixed-dose oral combination

Corium, a US-based biopharmaceutical firm, is focused on the development, manufacture and commercialization of specialty transdermal products. The MicroCor system is a clinical-stage platform technology using dissolving microstructures

Nanotherapeutics acquired Vero cell technology from Baxalta, formerly Baxter International’s BioScience division. Earlier in 2010, Takeda licensed from Baxter certain exclusive rights to the technology to develop pandemic